RE: Where are we now?15 Oct 2018 15:15
Dallo,
I am glad that we can agree on the finer points :-)
Lupuzor is the key of course.... and everyone in the "lupus market " is keeping their eyes riveted on the FDA....
If the FDA allow for changes in the primary endpoints for clinical trials in Lupus....this will open the door for "partnerships" and Lupuzor should or could benefit from this...imv